Resultados da busca - Foley JE

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus por Dejager S, Schweizer A, Foley JE

Obter o texto integral

DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes por Kozlovski P, Bhosekar V, Foley JE

Obter o texto integral

Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes... por Evans M, Schweizer A, Foley JE

Obter o texto integral

Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients? por Foley JE, Bhosekar V, Kawamori R

Obter o texto integral

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies por Schweizer A, Dejager S, Foley JE, Kothny W

Obter o texto integral

Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes por Blüher M, Schweizer A, Bader G, Foley JE

Obter o texto integral

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin por Schweizer A, Foley JE, Kothny W, Ahrén B

Obter o texto integral

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment por Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W

Obter o texto integral